180 related articles for article (PubMed ID: 18797467)
1. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.
Fens MH; Hill KJ; Issa J; Ashton SE; Westwood FR; Blakey DC; Storm G; Ryan AJ; Schiffelers RM
Br J Cancer; 2008 Oct; 99(8):1256-64. PubMed ID: 18797467
[TBL] [Abstract][Full Text] [Related]
2. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Martinelli M; Bonezzi K; Riccardi E; Kuhn E; Frapolli R; Zucchetti M; Ryan AJ; Taraboletti G; Giavazzi R
Br J Cancer; 2007 Oct; 97(7):888-94. PubMed ID: 17848949
[TBL] [Abstract][Full Text] [Related]
3. ZD6126: a novel small molecule vascular targeting agent.
Blakey DC; Ashton SE; Westwood FR; Walker M; Ryan AJ
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1497-502. PubMed ID: 12459377
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
5. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
6. Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Kleespies A; Köhl G; Friedrich M; Ryan AJ; Barge A; Jauch KW; Bruns CJ
Neoplasia; 2005 Oct; 7(10):957-66. PubMed ID: 16242078
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
LoRusso PM; Gadgeel SM; Wozniak A; Barge AJ; Jones HK; DelProposto ZS; DeLuca PA; Evelhoch JL; Boerner SA; Wheeler C
Invest New Drugs; 2008 Apr; 26(2):159-67. PubMed ID: 18219445
[TBL] [Abstract][Full Text] [Related]
8. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
Huang FY; Mei WL; Li YN; Tan GH; Dai HF; Guo JL; Wang H; Huang YH; Zhao HG; Zhou SL; Li L; Lin YY
Eur J Cancer; 2012 Sep; 48(14):2260-9. PubMed ID: 22257793
[TBL] [Abstract][Full Text] [Related]
9. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):846-53. PubMed ID: 15936569
[TBL] [Abstract][Full Text] [Related]
10. Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice.
D'Souza RA; Partridge EA; Roberts DW; Ashton S; Ryan A; Patterson AB; Wilson Z; Thurrell CC
Xenobiotica; 2007 Mar; 37(3):328-40. PubMed ID: 17624029
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
14. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
15. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.
McCarty MF; Takeda A; Stoeltzing O; Liu W; Fan F; Reinmuth N; Akagi M; Bucana C; Mansfield PF; Ryan A; Ellis LM
Br J Cancer; 2004 Feb; 90(3):705-11. PubMed ID: 14760388
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
Beerepoot LV; Radema SA; Witteveen EO; Thomas T; Wheeler C; Kempin S; Voest EE
J Clin Oncol; 2006 Apr; 24(10):1491-8. PubMed ID: 16574998
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of radiation response with the vascular targeting agent ZD6126.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
[TBL] [Abstract][Full Text] [Related]
18. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
[TBL] [Abstract][Full Text] [Related]
19. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
[TBL] [Abstract][Full Text] [Related]
20. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
